Get started
Author

Lucy V. Armstrong

Observed name: Lucy Armstrong
ORCID: 0000-0003-2484-8930
Observed ORCIDs: 0000-0003-2484-8930, 0000-0003-0627-2704
OpenAlex ID: A5065995313
Tractography of the Brainstem in Major Depressive Disorder Using Diffusion Tensor Imaging
2014 · Yun Ju C. Song, Mayuresh S. Korgaonkar, et al. · PLoS ONE · 46
PDF
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024 · Patrick G. Pilié, Virginia Giuliani, et al. · Clinical Cancer Research · 21
PDF
ERCC6L2 mitigates replication stress and promotes centromere stability
2023 · Christopher J. Carnie, Lucy Armstrong, et al. · Cell Reports · 21
PDF
Quantitative, titratable and high-throughput reporter assays to measure DNA double strand break repair activity in cells
2023 · Eeson Rajendra, Diego Grande, et al. · Nucleic Acids Research · 20
PDF
Worry and Depression in the Old and Young: Differences and Mediating Factors
2014 · Lucy Armstrong, Viviana M. Wuthrich, et al. · Behaviour Change · 8
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy
2025 · Eeson Rajendra, Claudio A Lademann, et al. · Nucleic Acids Research · 7
Do voice-hearing assessment measures capture the positive experiences of individuals, and to what extent? A systematic review of published assessment measures
2021 · Lucy V. Armstrong, Lorna Hogg, et al. · Psychosis · 6
PDF
The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al. · Clinical Cancer Research · 2
Abstract 2905: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors
2025 · Helen M. Robinson, Desiree Piscitello, et al. · Cancer Research · 2
Data from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Supplementary Data1 from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Abstract 246: Discovery and mechanistic characterisation of the first oral bioavailable FEN1 inhibitor for treatment of HRD and EWS cancers and combination with various DDR inhibitors.
2026 · Lars T. Burgdorf, Julien Lefranc, et al. · Cancer Research
Data from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024 · Patrick G. Pilié, Virginia Giuliani, et al.
Supplementary Table S1 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024 · Patrick G. Pilié, Virginia Giuliani, et al.
Supplementary S1-S8 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
2024 · Patrick G. Pilié, Virginia Giuliani, et al.
How well do voice-hearing assessment measures capture the positive experiences of individuals?
2019 · Lucy Armstrong, Lorna Hogg, et al. · PsyArXiv (OSF Preprints)
Works count: 16
Citation count: 133
H-index: 6
I10-index: 4
Year
Topic
Type